repaglinide

This non-sulfonylurea insulin secretagogue specifically binds to the 36KDA protein on the ATP-dependent potassium ion channel outside the insulin cell membrane, closing the potassium channel, depolarizing the cell, opening the calcium channel, and causing calcium ion influx, thus promoting insulin secretion. It works faster than sulfonylureas, so it has a faster effect in lowering blood sugar after a meal.

The main ingredient is repaglinide

Patients with type 2 diabetes (non-insulin-dependent) whose hyperglycemia cannot be effectively controlled by diet control, weight loss and exercise. Repaglinide can be used in combination with metformin. Compared with the use of each alone, the combination of the two has a synergistic effect on controlling blood sugar.

Repaglinide tablets should be taken before the main meal (i.e. before meals). The insulin secretion response occurs within 30 minutes of oral administration of repaglinide tablets. This drug is usually taken within 15 minutes before meals. The medication time can also be controlled within 0 to 30 minutes before meals. Please take repaglinide tablets as prescribed by your doctor. The dosage varies from person to person and depends on personal blood sugar. The recommended starting dose is 0.5 mg, which can be adjusted weekly or every two weeks if necessary. Patients receiving other oral hypoglycemic drugs can be directly switched to repaglinide tablets for treatment. The recommended starting dose is 0.5 mg. The maximum recommended single dose is 4 mg, taken with meals. However, the maximum daily dose should not exceed 16 mg. For patients with weakness and malnutrition, the dose should be adjusted with caution. If used in combination with metformin, the dose of repaglinide tablets should be reduced.

1. Hypoglycemia These reactions are usually mild and easily corrected by administering carbohydrates. If severe, glucose can be infused. 2. Visual abnormalities Changes in blood sugar levels are known to cause temporary visual abnormalities, especially at the beginning of treatment. Only very few cases have reported the above-mentioned visual abnormalities at the beginning of treatment with repaglinide tablets, but there have been no cases in clinical trials where repaglinide tablets were discontinued for this reason. 3. Gastrointestinal tract Gastrointestinal reactions such as abdominal pain, diarrhea, nausea, vomiting and constipation have been reported in clinical trials. Compared with other oral hypoglycemic drugs, there is no difference in the frequency and severity of these symptoms. 4. Liver enzyme system Individual cases reported elevated liver enzyme indicators during treatment with repaglinide tablets. Most cases were mild and temporary, and treatment was discontinued due to elevated enzyme indicators.

1. Patients with known hypersensitivity to repaglinide or any excipients in this product. 2. Patients with type 1 diabetes mellitus (insulin-dependent, IDDM). 3. Patients with diabetic ketoacidosis with or without coma. 4. Pregnant or lactating women. Children under 58 years old. 6. Patients with severe renal or hepatic impairment. 7. When combined with CYP3A4 inhibitors or inducers.

1 The following drugs can enhance the hypoglycemic effect of repaglinide tablets: monoamine oxidase inhibitors (MAOI), non-selective b-receptor blockers, ACE inhibitors, nonsteroidal anti-inflammatory drugs, salicylates, octreotide, alcohol and anabolic hormones. b-receptor blockers may mask the symptoms of hypoglycemia. Alcohol may aggravate or prolong the symptoms of hypoglycemia caused by repaglinide tablets. 2 The following drugs can weaken the hypoglycemic effect of repaglinide tablets: oral contraceptives, thiazides, corticosteroids, danazol, thyroid hormones and sympathomimetics. 3 Repaglinide tablets do not affect the pharmacokinetic properties of digoxin, theophylline and warfarin, and cimetixidine does not affect the pharmacokinetic properties of repaglinide tablets. 4 In vitro study results show that repaglinide tablets are mainly metabolized by P450 (CYP3A4) inducers. Therefore, CYP3A4 inhibitors such as ketoconazole, itraconazole, erythromycin, fluconazole, and mibifadil may increase the plasma levels of repaglinide tablets. Compounds that can induce CYP3A4, such as rifampicin or phenytoin, may reduce the plasma level of repaglinide tablets. Because the extent of their induction or inhibition is unknown, the combined use of the above drugs with repaglinide tablets should be contraindicated.

Sealed storage

Beijing Foyou Pharma Co., Ltd.

• Founded in:

  1999-02-03

• Address:

  No. 8 Guangyuan East Street, Tongzhou Industrial Development Zone, Tongzhou District, Beijing

• Tax NO.:

  91110112700216160K

• Registered Funds:

  480 million yuan

• Website:

  Log in to view

• Email:

  Log in to view